RxDoctor Payments Data

Aruna Potti, MD

Internal Medicine · Dallas, TXNPI 1649372749

Payments from drug & device makers

$3,181in general payments, 2019–2025

Across 196 payments — averaging $16.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$565
  • AstraZeneca$379
  • Novo Nordisk$348
  • AbbVie$282
  • Pfizer$270
  • Sanofi-aventis U.S. LLC$255
  • plus $1K from 18 others

What the payments were for

  • Speaking & faculty fees$1745%
  • Food & beverage$2,99094%
  • Education$181%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,181 in reported general payments places this provider in the 80th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$78,853
Medicare patients
145
Services billed
825

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide68$91,281
OzempicSemaglutide59$75,490
JardianceEmpagliflozin70$67,547
EliquisApixaban74$53,513
TrulicityDulaglutide19$23,432
JanuviaSitagliptin Phosphate20$21,289
FarxigaDapagliflozin Propanediol16$20,269
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$16,325
XareltoRivaroxaban20$11,578
LinzessLinaclotide22$11,481
MyrbetriqMirabegron25$11,128
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog12$9,948
Tresiba Flextouch U-100Insulin Degludec12$7,977
Fluticasone-SalmeterolFluticasone Propion/Salmeterol45$4,669
Lantus SolostarInsulin Glargine,hum.Rec.Anlog27$3,635

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$565$114,71387 claims
Novo NordiskOzempic$348$75,49059 claims
Boehringer IngelheimJardiance$15$67,54770 claims
PfizerEliquis$270$53,51374 claims
AstraZenecaFarxiga, Symbicort$379$23,69029 claims
MerckJanuvia$149$21,28920 claims
GSKTrelegy Ellipta$79$16,32515 claims
AbbVieLinzess, Synthroid$282$12,77557 claims
Astellas Pharma US IncMyrbetriq$17$11,12825 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →